Delineating the molecular mechanisms of hepatocyte-to-cholangiocyte reprogramming

描述肝细胞到胆​​管细胞重编程的分子机制

• 批准号: 10415302
• 负责人: Donghun Shin
• 金额: $ 51.49万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10415302
• 关键词: Bile fluid; Biliary; Cell model; Characteristics; Chemicals; Cholestasis; Cirrhosis; Data; EP300 gene; Epithelial Cells; Exhibits; Fibrosis; Gene Expression Regulation; Genes; Genetic; Genetic study; Goals; HDAC1 gene; Hepatic; Hepatocyte; Histone Acetylation; Image; Injury; Intrahepatic bile duct; Life; Liver; Liver Failure; Liver Regeneration; Liver diseases; MS-275; Mediating; Modeling; Molecular; Morbidity - disease rate; Mus; Natural regeneration; Obstruction; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacology; Pharmacology Study; Phenocopy; Process; Receptor Gene; Research; Role; Signal Transduction; Stat3 protein; Testing; Therapeutic; Zebrafish; base; beta catenin; biliary tract; cholangiocyte; effective therapy; end stage liver disease; gain of function; inhibitor; innovation; insight; liver injury; liver transplantation; mortality; mutant; notch protein; novel; small molecule; tool; transdifferentiation

ABSTRACT Biliary epithelial cells (BECs; also called as cholangiocytes) that line the hepatic biliary tree control bile composition and flow. Injury to the BECs leads to cholestasis, which can progress to fibrosis, cirrhosis and liver failure. Cholestatic liver diseases are associated with high morbidity and mortality; however, few effective therapies are available. In fact, liver transplantation is the only life-extending treatment for end-stage cholestatic liver diseases, but the shortage of donor livers makes this therapy extremely limited. In the injured liver with biliary damage, hepatocytes (HCs) can contribute to BECs to recover from the loss of BECs. Recent studies in mice have shown that HC-derived BECs contribute to the intrahepatic bile ducts, thereby restoring appropriate bile flow. Patients with biliary obstruction or cholangiopathies also exhibit biliary marker expression in HCs, suggesting their reprogramming into BECs. Thus, augmenting innate HC-to-BEC reprogramming in cholestatic liver diseases is an attractive therapeutic alternative to ameliorate cholestasis and subsequent cirrhosis. To develop such a therapy, it is crucial to better understand the molecular mechanisms underlying HC-to-BEC reprogramming. Furthermore, identifying small molecules that can augment the reprogramming should provide promising therapeutic drugs for patients with cholestatic liver diseases. Our long-term goal is to completely delineate the molecular mechanisms underlying HC-to-BEC reprogramming. As a first step in pursuit of that goal, the objective of this proposal is to determine the cellular and molecular characteristics of HC-to-BEC reprogramming-driven biliary regeneration in our two innovative zebrafish models and to elucidate how histone deacetylase 1 (hdac1) regulates HC-to-BEC reprogramming. Based on our preliminary data obtained from pharmacological and genetic studies, we hypothesize that Hdac1 inhibition promotes HC-to-BEC reprogramming by derepressing the Notch receptor gene notch2 and the signal transducer and activator of transcription 3 gene (stat3). We will test this hypothesis and accomplish the objective of this application by (1) elucidating the entire process of HC-to-BEC reprogramming-driven biliary regeneration in the two zebrafish models, in which complete absence of BECs is achieved and subsequently HCs convert to BECs. (Aim 1), (2) determining the effects of Hdac1 inhibition on HC-to-BEC reprogramming in both zebrafish and mice (Aim 2), and (3) elucidating the molecular mechanisms by which Hdac1 inhibition promotes the reprogramming (Aim 3). The successful accomplishment of the proposed research will not only provide novel molecular mechanisms underlying HC-to- BEC reprogramming but also suggest HDAC1/2 inhibitors as promising therapeutic drugs to promote the reprogramming in patients with cholestatic liver diseases.

摘要 胆管上皮细胞（BEC;也称为胆管细胞）排列在肝胆管树上，控制胆汁 组成和流动。BEC的损伤导致胆汁淤积，其可进展为纤维化、肝硬化和肝硬化。 失败胆汁淤积性肝病与高发病率和死亡率相关;然而，很少有有效的治疗方法。 治疗是可行的。事实上，肝移植是终末期胆汁淤积症唯一的延长生命的治疗方法 肝脏疾病，但供体肝脏的短缺使得这种治疗非常有限。在受伤的肝脏中， 在胆损伤中，肝细胞（HC）可有助于BEC从BEC的损失中恢复。的近期研究 小鼠已经表明，HC衍生的BEC有助于肝内胆管，从而恢复适当的 胆汁流量胆道梗阻或胆管病患者也表现出HC中的胆汁标志物表达， 表明它们被重新编程为BEC。因此，在胆汁淤积性疾病中增加先天性HC-至-BEC重编程， 肝病是改善胆汁淤积和随后的肝硬化的有吸引力的治疗选择。到 为了开发这种疗法，更好地理解HC到BEC的分子机制至关重要 重新编程此外，识别可以增强重编程的小分子应该提供 胆汁淤积性肝病患者的有前途的治疗药物。我们的长期目标是 描述HC到BEC重编程的分子机制。作为实现这一目标的第一步， 本计划的目的是确定HC-到-BEC的细胞和分子特征 在我们的两个创新的斑马鱼模型中重新编程驱动的胆汁再生，并阐明组蛋白如何 去乙酰化酶1（hdac 1）调节HC到BEC的重编程。根据我们从以下机构获得的初步数据， 通过药理学和遗传学研究，我们假设Hdac 1抑制促进HC到BEC的重编程 通过去抑制Notch受体基因notch 2和信号转导和转录激活因子3基因， （stat3）。我们将测试该假设并通过以下方式实现本申请的目的：（1）阐明整个实施例， 在两种斑马鱼模型中，HC到BEC重编程驱动的胆汁再生过程，其中完全 实现了BEC的不存在，随后HC转化为BEC。(Aim（1）、（2）确定影响 Hdac 1对斑马鱼和小鼠中HC-至-BEC重编程的抑制（目的2），和（3）阐明Hdac 1对HC-至-BEC重编程的抑制作用。 Hdac 1抑制促进重编程的分子机制（Aim 3）。成功 这项研究的完成不仅将提供HC-到-- BEC重编程，但也表明HDAC 1/2抑制剂作为有前途的治疗药物，以促进 胆汁淤积性肝病患者的重编程。